DUBLIN--(BUSINESS WIRE)--The "Alpha-Antitrypsin Deficiency - Epidemiology Forecasts to 2027" report has been added to ResearchAndMarkets.com's offering.
This report provides a comprehensive analysis of the disease epidemiology in the 7MM (United States, Germany, France, Italy, Spain, UK and Japan). The study period of the report is 2017-2027. This report provides understanding of the patients affected, diagnostic patterns, treatment trends and unmet medical needs.
The disease epidemiology covered in the report is segmented into two parts: Population at the risk of developing AATD on the basis of allele (PiSS, PiSZ, PiZZ) and Prevalent cases of AATD in 6 Major Markets (United States and EU5 (Germany, Spain, Italy, France and United Kingdom). Population at risk of Alpha-1-Antitrypsin Deficiency has been calculated on the basis of direct epidemiological approach that uses findings of genetic epidemiological surveys. As AATD is quite rare in Japan, the report features the diagnosed population of AATD in Japan.
Report Scope
- The report covers detailed overview of Alpha-Antitrypsin Deficiency (AATD) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The report provides the insight about the historical and forecasted patient pool of Alpha-Antitrypsin Deficiency (AATD) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
- The report assesses the disease risk and burden and highlights the unmet needs of the disease
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report provides the population at risk of developing AATD and prevalence of AATD in 6MM and diagnosed population of AATD in Japan
Key Topics Covered:
1. Report Introduction
2. Alpha Antitrypsin Deficiency Epidemiology Overview at a Glance
3. Disease Background and Overview: Alpha Antitrypsin Deficiency
4. Epidemiology and Patient Population
5. Appendix
6. Report Methodology
For more information about this report visit https://www.researchandmarkets.com/research/97wdr8/alphaantitrypsin?w=4
